12.08
Delcath Systems Inc stock is traded at $12.08, with a volume of 213.50K.
It is down -1.06% in the last 24 hours and down -25.80% over the past month.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
See More
Previous Close:
$12.21
Open:
$12.44
24h Volume:
213.50K
Relative Volume:
0.55
Market Cap:
$403.51M
Revenue:
$2.07M
Net Income/Loss:
$-47.68M
P/E Ratio:
-4.2837
EPS:
-2.82
Net Cash Flow:
$-31.31M
1W Performance:
-8.62%
1M Performance:
-25.80%
6M Performance:
+26.62%
1Y Performance:
+215.40%
Delcath Systems Inc Stock (DCTH) Company Profile
Name
Delcath Systems Inc
Sector
Industry
Phone
(518) 743-8892
Address
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
DCTH
Delcath Systems Inc
|
12.08 | 403.51M | 2.07M | -47.68M | -31.31M | -2.82 |
![]()
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
![]()
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-28-24 | Initiated | Craig Hallum | Buy |
May-14-24 | Initiated | Stephens | Overweight |
Jul-26-22 | Resumed | Canaccord Genuity | Buy |
Dec-10-21 | Initiated | H.C. Wainwright | Buy |
Mar-09-21 | Initiated | Canaccord Genuity | Buy |
Jan-05-21 | Initiated | BTIG Research | Buy |
Jun-01-20 | Initiated | Laidlaw | Buy |
View All
Delcath Systems Inc Stock (DCTH) Latest News
Delcath Systems Reports Strong 2024 Financial Growth - TipRanks
Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2024 Earnings Call Transcript - MSN
With A 27% Price Drop For Delcath Systems, Inc. (NASDAQ:DCTH) You'll Still Get What You Pay For - Simply Wall St
Delcath Systems’ Earnings Call Highlights Strong Growth and Strategic Expansion - TipRanks
HC Wainwright Estimates Delcath Systems FY2029 Earnings - Defense World
Delcath Systems (NASDAQ:DCTH) Price Target Raised to $24.00 - Defense World
Earnings Beat: Delcath Systems, Inc. (NASDAQ:DCTH) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance UK
Private Advisor Group LLC Acquires New Position in Delcath Systems, Inc. (NASDAQ:DCTH) - Defense World
Positive Outlook for Delcath Systems: Promising Growth and Strategic Expansion Drive Buy Rating - TipRanks
Delcath stock price target raised to $24 by H.C. Wainwright - Investing.com India
Strong Growth Potential for Delcath Systems: Buy Rating Affirmed with Raised Price Target - TipRanks
Delcath Systems reports net loss of USD 3.4M in Q4 2024 - Medical Buyer
Here's Why We're Not Too Worried About Delcath Systems' (NASDAQ:DCTH) Cash Burn Situation - Yahoo Finance
Delcath Systems Inc (DCTH) Q4 2024 Earnings Call Highlights: Strong HEPZATO Revenue and ... - Yahoo Finance
Delcath Systems Braces for Financial Impact Amid Uncertain Tax Law Changes - TipRanks
Delcath Systems, Inc. (DCTH) Beats Q4 Earnings and Revenue Estimates - MSN
BTIG lifts Delcath Systems stock target to $22, maintains buy By Investing.com - Investing.com Canada
BTIG lifts Delcath Systems stock target to $22, maintains buy - Investing.com
Delcath Systems reports Q4 EPS (11c), consensus 1c - TipRanks
Delcath Systems Inc reports results for the quarter ended December 31Earnings Summary - TradingView
DELCATH SYSTEMS, INC. SEC 10-K Report - TradingView
Earnings call transcript: Delcath Systems Q4 2024 results show mixed performance - Investing.com
Delcath Systems Inc (DCTH) Q4 Earnings: Revenue Surpasses Estima - GuruFocus.com
Delcath Systems Inc. Q4 Loss Decreases, But Misses Estimates - Nasdaq
Can Delcath's 30x Revenue Growth and FDA Trial Approval Transform Cancer Treatment? - StockTitan
Delcath Systems, Inc. (NASDAQ:DCTH) Shares Acquired by Principal Financial Group Inc. - Defense World
Carcinoid Tumor Treatment Market Size in the 7MM is expected - openPR
Delcath Systems Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
(DCTH) Proactive Strategies - Stock Traders Daily
The future of U.S. medical devices companies amid tariff impositions (IHI:NYSEARCA) - Seeking Alpha
Is Corcept Therapeutics (CORT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Delcath Systems (DCTH) Expected to Announce Earnings on Thursday - Defense World
Painful week for retail investors invested in Delcath Systems, Inc. (NASDAQ:DCTH) after 14% drop, institutions also suffered losses - Simply Wall St
Where are the Opportunities in (DCTH) - Stock Traders Daily
Liver Cancer Treatment Pioneer Delcath Reports Q4 Earnings: Will Growth Continue? - StockTitan
Intrahepatic Cholangiocarcinoma Market: Analysis - openPR
Here's What Could Help Delcath Systems (DCTH) Maintain Its Recent Price Strength - Nasdaq
Delcath Systems Announces Update To National Comprehensive Cancer Network Clinical Practice Guidelines - Marketscreener.com
Delcath Systems Announces Update to National Comprehensive Cance - WICZ
Major Treatment Breakthrough: NCCN Widens Access to Revolutionary Melanoma Therapy - StockTitan
Are You Looking for a Top Momentum Pick? Why Delcath Systems, Inc. (DCTH) is a Great Choice - MSN
Delcath Delivers 100% Gain In Less Than 6 Months - RTTNews
Analysts Say Delcath Systems Inc Can Reach $22 In 12 Months - Marketing Sentinel
Delcath Systems: Strong Position In Metastatic Uveal Melanoma, But Broader Growth Challenges Ahead - Seeking Alpha
Wall Street Analysts Think Delcath Systems (DCTH) Could Surge 33.74%: Read This Before Placing a Bet - Nasdaq
How should investors view Delcath Systems Inc (DCTH)? - US Post News
Law Offices of Todd M. Garber Announces Class Action Lawsuit Against Delcath Systems, Inc. - AOL
16,978 Shares in Delcath Systems, Inc. (NASDAQ:DCTH) Acquired by Baader Bank Aktiengesellschaft - MarketBeat
Delcath Systems, Inc. (NASDAQ:DCTH) Short Interest Update - MarketBeat
Delcath Systems Inc Stock (DCTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):